Dianthus Therapeutics (DNTH) closed at $91.81 on November 13, 2026, down 0.7% from the previous close, on volume of 635,102 shares (30-day average 914,809).
Data as of November 13, 2026.
13-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 20, 2026 | Strangle or Risk Reversal | 18-Dec-2665 P : 85 C | 3,000 |
| 2-2 | The next 1 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 13, 2026. See the 10 largest for 30, 60 and 90 days
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks (Fri, 13-Nov 10:30 AM ET)
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 2026 Financial Results
Globe Newswire (Wed, 4-Nov 4:01 PM ET)
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Mon, 2-Nov 5:00 PM ET)
Dianthus Therapeutics to Participate in Five Investor Conferences During November
Globe Newswire (Mon, 2-Nov 4:01 PM ET)
Dianthus Therapeutics Recognized Among Fortune's 2026 Best Workplaces In BioPharma
Globe Newswire (Tue, 13-Oct 8:45 AM ET)
Globe Newswire (Tue, 29-Sep 8:00 AM ET)
Dianthus Therapeutics to Participate in Three Investor Conferences During September
Globe Newswire (Tue, 1-Sep 8:00 AM ET)
Market Chameleon (Wed, 11-Mar 4:16 AM ET)
Dianthus Therapeutics Sparks Attention with Phase 3 CIDP Trial Update—Market Awaits Conference Call
Market Chameleon (Mon, 9-Mar 6:32 AM ET)
DNTH Secures Early Phase 3 Milestone in CIDP as Cash Runway Extends Into 2028
Market Chameleon (Mon, 9-Mar 3:57 AM ET)
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.
Dianthus Therapeutics trades on the NASDAQ stock market under the symbol DNTH.
As of November 13, 2026, DNTH stock price declined to $91.81 with 635,102 million shares trading.
DNTH has a beta of -0.13, meaning it tends to be less sensitive to market movements. DNTH has a correlation of 0.00 to the broad based SPY ETF.
DNTH has a market cap of $5.17 billion. This is considered a Mid Cap stock.
Last quarter Dianthus Therapeutics reported $1 million in Revenue and -$.81 earnings per share. This beat revenue expectation by $759,072 and exceeded earnings estimates by $.15.
In the last 3 years, DNTH traded as high as $117.88 and as low as $6.58.
The top ETF exchange traded funds that DNTH belongs to (by Net Assets): VTI, XBI, IWM, VXF, VB.
DNTH has outperformed the market in the last year with a price return of +158.6% while the SPY ETF gained +13.4%. However, in the short term, DNTH had mixed performance relative to the market. It has underperformed in the last 3 months, returning -16.2% vs -2.8% return in SPY. But in the last 2 weeks, DNTH shares have fared better than the market returning +11.4% compared to SPY -0.2%.
DNTH support price is $89.19 and resistance is $95.77 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that DNTH shares will trade within this expected range on the day.
